Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Exenatide Implant

Next Previous
X
Search
Trial Profile

A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Exenatide Implant

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary) ; Exenatide; Semaglutide
  • Indications Obesity
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms LIBERATE-1
  • Sponsors Vivani Medical

    • Most Recent Events

    • 17 Feb 2025 Status changed from recruiting to active, no longer recruiting.
    • 19 Dec 2024 Status changed from not yet recruiting to recruiting as per a Vivani Medical media release.
    • 26 Sep 2024 According to a Vivani Medical media release, the Company announced that the Bellberry Human Research Ethics Committee (HREC) has approved and the Therapeutic Goods Administration (TGA) in Australia has formally acknowledged a first in human clinical trial of the Company's miniature, subdermal GLP-1 (exenatide) implant in obese and overweight subjects.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top